The vaccine contains a strain of chikungunya virus that has been attenuated. IXCHIQ comes from Valneva Canada and it is ...

November 13, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1-on-1 meetings with institutional investors at ...

Here is a breakdown of the information Valneva Se presented to its investors. Valneva SE is a specialty vaccine company focused on developing, manufacturing, and commercializing vaccines for ...

Valneva SE (INRLF) reports a significant turnaround with increased sales and a positive operating profit, despite challenges ...

Valneva (VALN) has released an update. Valneva SE has reported €116.6 million in total revenues for the first nine months of 2024, with a notable turnaround to a €24.7 million net profit, driven by ...

The global sales of attenuated vaccines are projected to soar, with an estimated worth of USD 5,068.2 million in 2024 and anticipated to reach USD 9,693.9 million by 2034. This growth trajectory ...

SINGAPORE – Two updated Covid-19 vaccines will be rolled out from Oct 28 at almost 500 clinics and 10 polyclinics, with the five remaining Joint Testing and Vaccination Centres (JTVCs ...

On Aug. 22, the Food and Drug Administration approved and authorized newer formulations of the two mRNA vaccines, from Pfizer/BioNTech and Moderna, for ages 6 months and up. About a week later ...

The Ministry of Health from Oct 28 will roll out the updated JN.1 Pfizer-BioNTech/Comirnaty and JN.1 Moderna/Spikevax vaccines. The vaccination is especially applicable to individuals at increased ...